02091nam a2200469 i 4500 ocn946944315 OCoLC 20160809093803.0 he bmb024bbca 160419s2015 dcua bb f000 0 eng c GPO eng rda GPO pcc n-us--- KF31 .F5 2015 1038-B (MF) Y 4.F 49:S.PRT.114-20/ Y 4.F 49:S.PRT.114-20/ The price of Sovaldi and its impact on the U.S. health care system / prepared by the staffs of ranking member Ron Wyden and committee member Charles E. Grassley, Committee on Finance, United States Senate. Washington : U.S. Government Publishing Office, 2015. Washington, DC : For sale by the Superintendent of Documents, U.S. Government Publishing Office 2 volumes (viii, 1980 pages) : illustrations ; 24 cm. txt h rdamedia he rdacarrier S. prt. ; 114-20 At head of title: 114th Congress, 1st session. Committee print. Shipping list no.: 2016-0082-M. "December 2015." CRDP Project record. Includes bibliographical references. Microfiche. [Washington, D.C.] : U.S. Government Printing Office, [2016] 34 microfiches : negative. Sofosbuvir Prices United States. Hepatitis C Chemotherapy United States Costs. Sulfonamides Prices United States. Antiviral agents Prices United States. Gilead Sciences (Firm) Legislative materials. lcgft United States. Congress. Senate. Committee on Finance, issuing body. Print version: Price of Sovaldi and its impact on the U.S. health care system (OCoLC)932019028 Online version: Price of Sovaldi and its impact on the U.S. health care system (OCoLC)932136752 S. prt. ; 114-20. 253290 253290